Wolf Theiss advised Synthesis Capital on the legal aspects of their investment into Arkeon Biotechnologies, a startup which uses an ancient microbe to turn CO2 into ingredients for food.
A multidisciplinary team led by M&A Partner Sarah Wared advised Synthesis Capital on all legal aspects of the transaction from an Austrian law perspective (due diligence, advice in connection with the investment agreement and tax law).
Arkeon Biotechnologies is reimagining farming inside bioreactors in a lab: Using a single-step process of fermentation, it turns captured CO2 into ingredients for food. The company uses a microorganism with the unique ability to directly transform CO2 into the building blocks for carbon-negative protein. The resulting ingredients can be used in alternative protein products, such as plant-based milk or meat. The ingredients can also be used directly in protein drinks and infant formula.
Synthesis Capital is a venture capital investment firm based in London, United Kingdom. The firm invests in transformative food technology innovations, with a focus on the alternative protein ecosystem. The Synthesis Capital team have been investing in the food tech sector since 2014. More information on Synthesis Capital is available here.
In addition to Sarah Wared (Partner, Corporate / M&A), the Wolf Theiss core team consisted of Gregor Grablowitz (Associate, Corporate / M&A) and Karin Spindler-Simader (Consultant, Tax).